Exploration and Study of Jianpi Qushi Powder Combined with Standard Anti HP Quadruple Therapy in the Treatment of HP Infectious Gastritis of Spleen Deficiency and Dampness Stagnation Type
- 1 The Second Department of Internal Medicine of Guigang Integrated Traditional Chinese and Western Medicine Orthopedic Hospital, Guigang, China
- 2 Laboratory Department of People’s Hospital of Guangxi ASEAN Economic and Technological Development Zone, Nanning Tenth People’s Hospital, Nanning, China
- 3 Department of Nursing, Graduate College of Eternity University of the Philippines, Las Pinas, Philippines
- 4 People’s Hospital of Gangbei District, Guigang, China
- 5 The Second Department of Internal Medicine of Guigang Integrated Traditional Chinese and Western Medicine Orthopedic Hospital, Guigang, China
- 6 The Second Department of Internal Medicine of Guigang Integrated Traditional Chinese and Western Medicine Orthopedic Hospital, Guigang, China
- 7 The Second Department of Internal Medicine of Guigang Integrated Traditional Chinese and Western Medicine Orthopedic Hospital, Guigang, China
- 8 Department of Critical Care Medicine, Fuzhou Second People’s Hospital, Fuzhou, China
- 9 Department of Nursing, Vocational College of Liaoning Hospital, Shenyang, China
- 10 The Second Department of Internal Medicine of Guigang Integrated Traditional Chinese and Western Medicine Orthopedic Hospital, Guigang, China
- 11 The Second Department of Internal Medicine of Guigang Integrated Traditional Chinese and Western Medicine Orthopedic Hospital, Guigang, China
Abstract
Objective: To explore the therapeutic effect of traditional Chinese medicine Jianpi Qushi powder combined with standard anti-HP quadruple therapy in the treatment of HP infectious gastritis with spleen deficiency and dampness stagnation. Methods: From January 2020 to December 2021, 223 patients with laboratory-confirmed HP infection who were admitted to the Outpatient and Inpatient Department of Internal Medicine in our hospital were selected as the research objects and randomly divided into two groups. 101 patients in the control group were given standard anti HP quadruple therapy; 122 cases in the treatment group were given traditional Chinese medicine Jianpi Qushi powder combined with standard anti HP quadruple therapy. The two groups were rechecked carbon breath test after the designed course of treatment, and the curative effects of the two groups were compared. Results: 113 cases in the treatment group were cured by traditional Chinese medicine Jianpi Qushi powder combined with standard anti HP quadruple therapy, and the cure rate was 92.62%. 84 cases in the control group were cured by standard anti HP quadruple therapy, and the cure rate was 83.17%, χ 2 = 4.7955, P = 0.0285, the difference was statistically significant (P < 0.05). Conclusion: Traditional Chinese medicine Jianpi Qushi powder combined with standard anti HP quadruple therapy in the treatment of HP infectious gastritis with spleen deficiency and dampness stagnation is one of the best treatment schemes for HP infection. The results of this study achieve the best clinical treatment effect, and provide a more valuable and reliable method for the treatment of gastropathy in clinical internal medicine, which is worthy of popularization and application.
- Cui, C.C., Li, C.F. and Zhang, B. (2017) Research Status and Progress of Treatment Schemes for Helicobacter pylori Infection. Journal of Jilin University (Medical Edition), 43, 1287-1290.
- Technische Universität München, max-planck-gesellschaft zur förderung der wissenschaften e.v. Helicobacter pylori Vaccines: World Patent Organization, WO2017102779(A1). 2017-06-22.
- Boltin, D. and Shirin, H. (2019) Summary of the Israel Gastroenterology Association (Iga) Guidelines for the Management and Treatment of Helicobacter Pylori in 2019. Harefuah, 158, 398-403.
- Univ nat taiwa. Composition for the Prevention and the Treatment of Helicobacter pylori Infection: US, US2010298244(A1). 2010-11-25.
- Shiota, S. and Yamaoka, Y. (2014) Strategy for the Treatment of Helicobacter pylori Infection. Current Pharmaceutical Design, 20, 4489-4500. https://doi.org/10.2174/13816128113196660731
- Compagnie gervais danone. Streptococcus Thermophilus Strains for Treating Helicobacter pylori Infection: World Patent Organization, WO2014064488(A1). 2014-05-01.
- Shionogi & Co Ltd. Vaccine Composition for Infection of Helicobacter pylori: Japan, JP2000083671. 2000-03-28.
- Harris, A. (2001) Treatment of Helicobacter pylori. World Journal of Gastroenterology (English Version), 7, 303-307. https://doi.org/10.3748/wjg.v7.i3.303
- Chiron corp, chiron corporation. Helicobacter pylori Diagnostics: Canada, CA2270163(A1). 1998-06-25.
- Karolinska inst innovations abjonsson ann-bethwehelie rahm. Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection. World Patent Organization, WO2011139226(A1). 2011-11-10.
- Kimura ken (jp), kaken pharma co Ltd (JP). Composition for the Treatment of Helicobacter pylori Infection: US, US5618564. 1997-04-08.
- Go, M.F. and Fennerty, M.B. (1998) Treatment of Helicobacter pylori Infection. Current Opinion in Gastroenterology, 14, 64-69. https://doi.org/10.1097/00001574-199801000-00012
- Coton, T., Debonne, J.-M., Guisset, M., et al. (1997) L’infection a Helicobacter pylori dans les pays en developpement. Medecine Tropicale, 57, 77-82.
- Academia Sinica. Compositions and Assays for Treatment and Diagnosis of Helicobacter pylori Infection and Conditions: US, US8785402(B2). 2014-07-22.
- Chey, W.D., Leontiadis, G.I., Howden, C.W., et al. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology, 112, 212-239. https://doi.org/10.1038/ajg.2016.563